Large Real-World study tracks regorafenib in advanced colon cancer
NCT ID NCT02310477
First seen Mar 17, 2026 · Last updated May 10, 2026 · Updated 10 times
Summary
This study followed over 700 adults with metastatic colorectal cancer who took regorafenib as part of a French compassionate-use program. Researchers measured how long patients lived after starting the drug and looked at factors like tumor location and previous treatments. The goal was to understand real-world effectiveness, not to test a new cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Oscar Lambret
Lille, 59020, France
Conditions
Explore the condition pages connected to this study.